Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Diagnostics Company Chemclin Closes $16.5 Million Series B

publication date: Oct 23, 2008

Beijing Chemclin Biotech Co. completed a $16.5 million Series B round that it will use to further its diagnostics reagents business. The financing was led by a new investor, China Healthcare Partnership (managed by MC China), and it included existing investors, WI Harper, Siemens Venture Capital, and SB China Venture Capital. The investment bank China eCapital advised Chemclin in the transaction. Formed in 1999, Chemclin markets radioimmunoassay (RIA) kits, ELISA and chemiluminescent (CLIA) reagents. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital